Antonio Solana-Altabella

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Venues

Expert review of clinical pharmacology

Cancers

Leukemia & lymphoma

Medicine

IIS La Fe

This page only lists publications with an associated author ORCID identifier.

Affiliation History

IIS La Fe Oct 01 2019

Spain

Investigator :: Pharmacy

Publications

Antonio Solana-Altabella, Rebeca Rodriguez-Veiga, David Martínez-Cuadrón, Pau Montesinos
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold? Annals of hematology (2024)
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Expert review of clinical pharmacology 16 (2) (2023)
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Expert review of clinical pharmacology (2023)
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Expert review of clinical pharmacology (2023)
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Expert review of clinical pharmacology 16 (2) (2023)
Antonio Solana-Altabella, Emilio Monte-Boquet, Marta Montero, Pablo Pérez-Huertas, Maria Jesús Cuéllar-Monreal, Miguel Salavert, José Luis Poveda-Andrés
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus. Medicine 101 (49) (2023)
Blanca Boluda, Antonio Solana-Altabella, Isabel Cano, David Martínez-Cuadrón, Evelyn Acuña-Cruz, Laura Torres-Miñana, Rebeca Rodríguez-Veiga, Irene Navarro-Vicente, David Martínez-Campuzano, Raquel García-Ruiz, Pilar Lloret, Pedro Asensi, Ana Osa-Sáez, Jaume Aguero, María Rodríguez-Serrano, Francisco Buendía-Fuentes, Juan Eduardo Megías-Vericat, Beatriz Martín-Herreros, Eva Barragán, Claudia Sargas, Maribel Salas, Margaret Wooddell, Charles Dharmani, Miguel Angel Sanz, Javier de la Rubia, Pau Montesinos
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia. Cancers 15 (8) (2023)
Blanca Boluda, Antonio Solana-Altabella, Isabel Cano, David Martínez-Cuadrón, Evelyn Acuña-Cruz, Laura Torres-Miñana, Rebeca Rodríguez-Veiga, Irene Navarro-Vicente, David Martínez-Campuzano, Raquel García-Ruiz, Pilar Lloret, Pedro Asensi, Ana Osa-Sáez, Jaume Aguero, María Rodríguez-Serrano, Francisco Buendía-Fuentes, Juan Eduardo Megías-Vericat, Beatriz Martín-Herreros, Eva Barragán, Claudia Sargas, Maribel Salas, Margaret Wooddell, Charles Dharmani, Miguel Angel Sanz, Javier de la Rubia, Pau Montesinos
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia. Cancers 15 (8) (2023)
Antonio Solana-Altabella, Emilio Monte-Boquet, Marta Montero, Pablo Pérez-Huertas, Maria Jesús Cuéllar-Monreal, Miguel Salavert, José Luis Poveda-Andrés
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus. Medicine 101 (49) (2023)
Antonio Solana-Altabella, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Pau Montesinos
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. Expert opinion on emerging drugs 27 (1) (2022)
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, Blanca Boluda, Isabel Cano, Evelyn Acuña-Cruz, Rebeca Rodríguez-Veiga, Laura Torres-Miñana, Claudia Sargas, Miguel Angel Sanz, Carmela Borrell-García, Eduardo López-Briz, José Luis Poveda-Andrés, Javier de la Rubia, Pau Montesinos, David Martínez-Cuadrón
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study. Cancers 14 (8) (2022)
Mayte Gil-Candel, Antonio Solana-Altabella, Esther Vicente-Escrig, Aarón Puplá-Bartoll, Julia Bodega Azuara, Pablo Pérez-Huertas, Raul Ferrando Piqueres
Developing a telepharmacy programme with home medication dispensing and informed delivery in a tertiary hospital: description of the model and analysis of the results. European journal of hospital pharmacy : science and practice (2022)
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Antonio Solana-Altabella, José Luis Poveda-Andrés, Pau Montesinos
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia. Pharmaceutics 14 (4) (2022)
Blanca Boluda, Antonio Solana-Altabella, Isabel Cano, Evelyn Acuña-Cruz, Rebeca Rodríguez-Veiga, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Ines Gómez, Pilar Solves, Ignacio Lorenzo, Jose Luis Piñana, Jaime Sanz, Manuel Guerreiro, Juan Montoro Gómez, Alvaro Díaz-González, Javier Marco, Albert Blanco, Miguel Angel Sanz, Pau Montesinos
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain. Journal of clinical apheresis 36 (4) (2021)
Blanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, Isabel Cano, María J Sayas, Evelyn Acuña-Cruz, Albert Blanco, Javier Marco-Ayala, Rosalía DeLapuerta, Álvaro Díaz-González, María Del Mar Tormo Díaz, Rebeca Rodriguez-Veiga, Raimundo García, José Luis Piñana, María López-Pavía, Eva Barragán, María L Amigo, Claudia Sargas, Aurelio López, Antonio Solana-Altabella, Cristina Gil, Juan Eduardo Megías-Vericat, Miguel Angel Sanz, Pau Montesinos
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. Leukemia & lymphoma 62 (11) (2021)
Octavio Ballesta-López, Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Pau Montesinos
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Future oncology (London, England) 17 (2) (2020)
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, María José Herrero, Rebeca Rodríguez-Veiga, Antonio Solana-Altabella, Blanca Boluda, Octavio Ballesta-López, Isabel Cano, Evelyn Acuña-Cruz, José Cervera, José Luis Poveda, Miguel Angel Sanz, Salvador F Aliño, Pau Montesinos
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leukemia & lymphoma 62 (3) (2020)
Antonio Solana-Altabella, Silvia Valero, Julia Balaguer, Paloma Escobar-Cava, Honorio Barranco, Eduardo López, Hugo Ribes-Artero, Jose Luis Poveda
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (8) (2020)
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Antonio Solana-Altabella, Pau Montesinos
Precision medicine in acute myeloid leukemia: where are we now and what does the future hold? Expert review of hematology 13 (10) (2020)

Antonio Solana-Altabella.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Antonio Solana-Altabella